论文部分内容阅读
Ceftazidime(Fortum)是一种新型的第三代头孢菌素。1985年6月在日本京都召开的第14届国际化疗会议上,举行了一系列关于该药的临床治疗专题讨论,各国的实验室研究和临床应用已肯定Ceftazidime的疗效及其在抗感染治疗中的重要性。该品不仅对许多革蓝氏阴性杆菌包括绿脓杆菌在内具高度的抗菌力,而且许多革蓝氏阳性菌对其也很敏感,因而对病原菌不明的感染显示独特的治疗价值。对粒细胞减少的感染病例,单独投用Ceftazidime的疗效至少与其他抗生素的联合治疗同样有效。该
Ceftazidime (Fortum) is a new third generation cephalosporin. In June 1985 at the 14th International Conference on Chemotherapy in Kyoto, Japan, a series of thematic discussions on the clinical treatment of this drug were held. The laboratory research and clinical application in various countries have affirmed the efficacy of Ceftazidime and its efficacy in anti-infective therapy The importance of This product not only has a high degree of antibacterial activity against many gram-negative bacilli, including Pseudomonas aeruginosa but also is sensitive to many Gram-positive bacteria, and thus shows unique therapeutic value against unidentified infections of pathogens. For neutropenic cases, Ceftazidime administered alone is at least as effective as any combination of other antibiotics. This